Table 2 Adverse events in bolus group and no bolus group
Characteristics | Before PSM | P value | After PSM | P value | ||
|---|---|---|---|---|---|---|
No-bolus (N = 275) No. of patients (%) | Bolus (N = 254) No. of patients (%) | No-bolus (N = 175) No. of patients (%) | Bolus (N = 175) No. of patients (%) | |||
Acute skin toxicity, n (%) | 0.936 | 0.555 | ||||
Grade 1–2 | 239 (86.9%) | 218 (85.83%) | 152 (86.86%) | 148 (84.57%) | ||
Grade 3–4 | 16 (5.82%) | 16 (6.3%) | 9 (5.14%) | 14 (8.00%) | ||
Unknown | 20 (7.28%) | 20 (7.87%) | 14 (8.00%) | 13 (7.43%) | ||
Late pneumonia, n (%) | 0.329 | 0.333 | ||||
No | 262 (95.27%) | 237 (93.30%) | 168 (96.00%) | 164 (93.71%) | ||
Yes (grade 1–2) | 13 (4.73%) | 17 (6.70%) | 7 (4.00%) | 11 (6.29%) | ||